A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer

Prior treatment

• Subjects with known lung damage caused by concurrent lung diseases.
• Subjects with arterial/venous thrombotic events within 1 month before enrollment.
• Subjects who had a serious infection within 1 month before enrollment.

Other illness

• Subjects with other malignant tumors in the past or at the same time.
• Subjects with a history of interstitial pneumonia/interstitial lung disease or non-infectious pneumonia requiring steroid treatment.
• Subjects with autoimmune, connective tissue or inflammatory diseases involving the lungs.
• Subjects with active pulmonary tuberculosis.
• Subjects with poorly controlled or severe cardiovascular diseases.
• History of immunodeficiency, including positive HIV test.

Other

• Subjects with known untreated or active central nervous system (CNS) tumor metastases.
• Subjects with clinically symptomatic, poorly controlled, or moderate or greater pleural effusion, pericardial effusion or peritoneal effusion.

• Voluntarily join this study, sign the informed consent, have good compliance, and can cooperate with follow-up.
• Female, aged 18-75 years old (including 18 and 75 years old, calculated on the day of signing the informed consent).
• Cervical cancer confirmed by tissue or cytological pathology.
• Expected survival ≥ 12 weeks.
• Normal function of important organs.
• Female subjects of fertility must have a negative serum HCG test within 7 days before the first dose of Investigational Medicinal Product (IMP), and must not be breastfeeding, and must agree to comply with contraceptive requirements from the signing of the informed consent until the last dose of the trial drug for 7 months.